142 related articles for article (PubMed ID: 31714078)
1. Molecular Docking as a Promising Predictive Model for Silver Nanoparticle-Mediated Inhibition of Cytochrome P450 Enzymes.
Wasukan N; Kuno M; Maniratanachote R
J Chem Inf Model; 2019 Dec; 59(12):5126-5134. PubMed ID: 31714078
[TBL] [Abstract][Full Text] [Related]
2. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
3. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations.
Niu L; Ding L; Lu C; Zuo F; Yao K; Xu S; Li W; Yang D; Xu X
J Ethnopharmacol; 2016 Sep; 191():350-359. PubMed ID: 27318274
[TBL] [Abstract][Full Text] [Related]
4. Rule-Based Prediction Models of Cytochrome P450 Inhibition.
Su BH; Tu YS; Lin C; Shao CY; Lin OA; Tseng YJ
J Chem Inf Model; 2015 Jul; 55(7):1426-34. PubMed ID: 26108525
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study.
Basińska-Ziobroń A; Daniel WA; Wójcikowski J
Pharmacol Rep; 2015 Dec; 67(6):1178-82. PubMed ID: 26481538
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of Hwang-Ryun-Hae-Dok-Tang on cytochrome P450 in human liver microsomes.
Lee SY; Jang H; Lee JY; Ma JY; Oh SJ; Kim SK
Xenobiotica; 2015 Feb; 45(2):131-8. PubMed ID: 25145883
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
9. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
11. Identification of cytochrome P450 isoforms involved in the metabolism of artocarpin and assessment of its drug-drug interaction.
Qu W; Liu X
Biomed Chromatogr; 2018 Apr; 32(4):. PubMed ID: 29166542
[TBL] [Abstract][Full Text] [Related]
12. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
13. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
14. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.
Lieu C; Shi J; Donat F; Van Horn R; Brian W; Newton J; Delbressine L; Vos R
Clin Pharmacokinet; 2002; 41 Suppl 2():19-26. PubMed ID: 12383041
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450.
Chiangsom A; Lawanprasert S; Oda S; Kulthong K; Luechapudiporn R; Yokoi T; Maniratanachote R
Drug Metab Pharmacokinet; 2016 Jun; 31(3):210-7. PubMed ID: 27212065
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine.
Fang J; Coutts RT; McKenna KF; Baker GB
Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):592-9. PubMed ID: 9840430
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.
Pan LP; Wijnant P; De Vriendt C; Rosseel MT; Belpaire FM
Br J Clin Pharmacol; 1997 Dec; 44(6):557-64. PubMed ID: 9431831
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in silico studies of interaction of synthetic 2,6,9-trisubstituted purine kinase inhibitors BPA-302, BP-21 and BP-117 with liver drug-metabolizing cytochromes P450.
Špičáková A; Kraus P; Gucký T; Kryštof V; Strnad M; Bazgier V; Otyepka M; Kubíčková V; Poruba M; Rácová Z; Zapletalová I; Anzenbacher P
Physiol Res; 2020 Dec; 69(Suppl 4):S627-S636. PubMed ID: 33646005
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
20. Effects of silver nanoparticles on rat hepatic cytochrome P450 enzyme activity.
Kulthong K; Maniratanachote R; Kobayashi Y; Fukami T; Yokoi T
Xenobiotica; 2012 Sep; 42(9):854-62. PubMed ID: 22458323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
